ASHI/BANFF Joint Scientific Meeting

The American Society for Histocompatibility and Immunogenetics (ASHI)/Banff Foundation for Allograft Pathology (BANFF) Joint Scientific Meeting is organized by The American Society for Histocompatibility and Immunogenetics (ASHI) and will be held from Sep 23 - 27, 2019 at David L. Lawrence Convention Center, Pittsburgh, Pennsylvania, United States of America.

CREDIT DESIGNATION STATEMENT:
Amedco LLC designates this live activity for a maximum of 33.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CHT, CHS, ABHI DIPLOMATES:
The American Board of Histocompatibility and Immunogenetics has approved the ASHI/Banff Joint Scientific Meeting content for a maximum of 33.25 contact hours (7.5 contact hours for Inspectors’ Workshop or 5.5 contact hours for Pre-Meeting and 25.75 contact hours for the meeting) or 4.9875 CECs (1.125 CECs for Inspector’s Workshop or .825 CECs for Pre-Meeting and 3.8625 CECs for the meeting) of continuing education hours for completing.

Description:
This year’s Joint Meeting is intended to promote collaboration between experts in solid organ transplant pathology and histocompatibility/immunogenetic. The objective of this alliance is advancing diagnostic testing for solid organ transplant recipients with a particular emphasis on the immunology and pathology of antibody-mediated rejection.

Learning Objectives:
The ASHI/Banff Joint Scientific Meeting will provide updates on basic Immunogenetics and on practice guidelines in clinical histocompatibility, immunogenetics, and transplantation.
The learning objectives are as follows:
• Review the emerging field of regenerative medicine and tissue engineering in the context of transplantation pathology
• Review and integrate via case presentation the top 10 pathologic lesions and top 10 histocompatibility testing concepts in solid organ rejection
• Understand current unmet needs in diagnosing rejection in the different types of solid organ transplants
• Review recent developments in novel treatments for chronic-active Antibody-mediated rejection
• Discuss the current state of transplant tolerance trials and tolerance biomarker analyses in the human clinical trials
• Understand the diversity of current immunotherapies and how HLA diversity impacts their success
• Understanding of the emerging area of 3-D organization of the genome
• Understand basic and emerging concepts of HCT and cellular therapies and the role of histocompatibility and immunogenetics

Additional Details will be posted as soon as they are available.